Skip to main content
Clinical Trials/NCT03380338
NCT03380338
Completed
N/A

Lifestyle Intervention in Patients With Diabetes Type 2 and the Association With the Gut Microbiota

Amsterdam UMC, location VUmc1 site in 1 country15 target enrollmentMay 11, 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
Type 2 Diabetes Mellitus
Sponsor
Amsterdam UMC, location VUmc
Enrollment
15
Locations
1
Primary Endpoint
Change in insulin senistivity
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

To investigate whether targeted lifestyle intervention (exercise), induces a change in intestinal fecal microbiota related to improved glycemic control and systemic inflammation in patients with DM type 2.

Detailed Description

Diet and exercise are the most beneficial lifestyle interventions in patients with diabetes mellitus (DM) type 2, causing an increase in glucose tolerance. One of the mechanisms through which these treatment modalities work might be explained through changes in the gut microbiota. Recent studies show that the chronic inflammatory status causing insulin resistance in DM type 2, is triggered by an increase in circulating bacterial lipopolysaccharide (LPS). Strict lifestyle intervention, such as exercise, so called Diabetes Bootcamp (DB), may manipulate the gut microbiota, reducing circulating LPS, causing an improvement of the insulin-mediated

Registry
clinicaltrials.gov
Start Date
May 11, 2016
End Date
June 29, 2017
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Amsterdam UMC, location VUmc
Responsible Party
Principal Investigator
Principal Investigator

Erik Serne

Principal Investigator

Amsterdam UMC, location VUmc

Eligibility Criteria

Inclusion Criteria

  • Subjects must meet the criteria for diabetes type 2 (a random blood sugar of \> 11.1 mmol/L and/or a fasting blood sugar lever of \>7.0 mmol/L and/or a blood sugar of \>11.1 mmol/L two hours after an oral glucose tolerance test and/or an HbA1c level of \>47 mmol/mol).
  • Male or female (post-menopausal)
  • Age above 45 years and below 70 years
  • BMI \>30 kg/m2
  • HbA1c \< 80 mmol/mol or \< 8,6% Subjects must use metformin
  • Stable medication use
  • Stable tension regulation (with or without medication)
  • Subjects should be able to give informed consent

Exclusion Criteria

  • A history of cardiovascular event (Cerebrovascular event, myocardial infarction or pacemaker implantation)
  • Severe-very severe lung emphysema (GOLD stage III-IV)
  • Use of any antibiotics or proton pump inhibitor (PPI) in the past three months
  • Use of any other antidiabetic medication besides metformin (e.g. SU-derivates, insulin)
  • Use of a platelet inhibitor or cumarin derivate during
  • Subjects participated in a lifestyle programme in the past 6 months (diet or exercise)

Outcomes

Primary Outcomes

Change in insulin senistivity

Time Frame: Before and after exercise, i.e. from first visit (0 weeks) untill last visit (13 weeks)

Rate of disappearance measured by the hyperinsulinemic-euglycemic clamp with stable glucose isotopes.

Change in capillary recruitment

Time Frame: Before and after exercise, i.e. from first visit (0 weeks) untill last visit (13 weeks)

Insulin-induced capillary recruitment in skeletal muscle and heart

Changes in gut microbiota composition upon exercise

Time Frame: At baseline, after 7 weeks, after 13 weeks

alfa-diversity, beta-diversity

Secondary Outcomes

  • Changes in resting energy expenditure(Before and after exercise)
  • Changes in continous cardiovascular monitoring(Before and after exercise)

Study Sites (1)

Loading locations...

Similar Trials